TW580387B - Pharmaceutical combination comprising tipranavir and ritonavir - Google Patents

Pharmaceutical combination comprising tipranavir and ritonavir Download PDF

Info

Publication number
TW580387B
TW580387B TW088119229A TW88119229A TW580387B TW 580387 B TW580387 B TW 580387B TW 088119229 A TW088119229 A TW 088119229A TW 88119229 A TW88119229 A TW 88119229A TW 580387 B TW580387 B TW 580387B
Authority
TW
Taiwan
Prior art keywords
direnavir
treatment
amount
gram
ritunavir
Prior art date
Application number
TW088119229A
Other languages
English (en)
Chinese (zh)
Inventor
James J Ferry
John R Baldwin
Marie T Borin
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of TW580387B publication Critical patent/TW580387B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW088119229A 1998-11-04 1999-11-04 Pharmaceutical combination comprising tipranavir and ritonavir TW580387B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04

Publications (1)

Publication Number Publication Date
TW580387B true TW580387B (en) 2004-03-21

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088119229A TW580387B (en) 1998-11-04 1999-11-04 Pharmaceutical combination comprising tipranavir and ritonavir

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ES2298286T3 (es) * 2000-10-31 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona.
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
KR20050085681A (ko) * 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
EP1610781A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
EP1812069A2 (en) * 2004-11-08 2007-08-01 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and etravirine
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
WO2006060175A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
WO2006060177A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
JP2008521896A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ６９５６３４を共に投与することを含むｈｉｖ感染症の治療方法
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
MX2012011415A (es) * 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
AU2012262322B2 (en) * 2011-05-30 2016-11-03 Autotelic Llc Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
JP2002528502A (ja) 2002-09-03
CO5160321A1 (es) 2002-05-30
EP1126847A1 (en) 2001-08-29
CN1154491C (zh) 2004-06-23
CN1324237A (zh) 2001-11-28
BR9914940A (pt) 2001-07-10
PE20001296A1 (es) 2000-11-23
CA2346131A1 (en) 2000-05-11
WO2000025784A1 (en) 2000-05-11
CA2346131C (en) 2013-01-15
AU762349B2 (en) 2003-06-26
MY118526A (en) 2004-11-30
AU1440400A (en) 2000-05-22
HK1040625B (zh) 2005-04-01
US6147095A (en) 2000-11-14
HK1040625A1 (en) 2002-06-21

Similar Documents

Publication Publication Date Title
Wang et al. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
Sohag et al. Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Peng et al. Current drugs for HIV-1: from challenges to potential in HIV/AIDS
RU2609512C2 (ru) Производные ингенола для реактивации латентного вируса вич
AU762349B2 (en) Method for improving the pharmacokinetics of tipranavir
CN101466392B (zh) 用于预防或治疗hiv感染的药用组合物及其应用
JPH11507632A (ja) 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
US12239629B2 (en) Methods for the prophylaxis and treatment of COVID and COVID-19
US20090042793A1 (en) Novel Antiviral Therapies
CA2793749A1 (fr) Nouveaux schemas d'administration de multitherapies utiles pour le traitement des personnes affectees par le virus de l'immunodeficience humaine (vih)
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
CA2460377A1 (fr) Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic
US10588896B2 (en) Agents for the treatment of retroviral infectious diseases
TWI800146B (zh) 魚針草酸用於製備抑制新型冠狀病毒與變異株等感染與複製之醫藥組合物的用途
KR102808954B1 (ko) 북극고래 유래 재조합 섬유아세포 성장인자 11을 유효성분으로 포함하는 항바이러스 조성물
US20060281673A1 (en) Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41
US20210378985A1 (en) Method and compound for the treatment of hepatitis c
US20230391837A1 (en) Methods of treating, ameliorating, and/or preventing covid-19 infection and related inflammation
EP4079864A1 (en) Method for identifying compounds modifying the activity of sars cov2 plpro protease, and uses of the compounds as identified
Chen et al. Discovery and development of the human immunodeficiency virus protease inhibitor Saquinavir
CN122031493A (zh) 一种药物组合物在制备抗流感病毒药物中的应用
Vanangamudi et al. Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy
Sension Initial Therapy for Human Immunodeficiency Virus: Broadening the Options
CN100464748C (zh) 消旋去甲胡桐素a制备抗爱滋病毒类药物的应用
CN106619591A (zh) 奥昔卡因在制备药物中的用途及药物组合物

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent